WF
PCRX icon

WealthTrust Fairport’s Pacira BioSciences PCRX Stock Holding History

WealthTrust Fairport’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-100
Closed -$9K – 398
2014
Q2 		$9K Buy
+100
New +$7.62K ﹤0.01% 239

Other funds holding PCRX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCM
Marsico Capital Management Denver, Colorado $3.4B AUM 51.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

WealthTrust Fairport's PCRX Position: Q3 2014 in Review

WealthTrust Fairport sold out of Pacira BioSciences (PCRX) in Q3 2014, closing a stake of 100 shares — an estimated $9K sold.

WealthTrust Fairport first reported a position in PCRX in Q2 2014 and held it in 1 quarter. The position peaked at $9K in Q2 2014. 208 funds tracked by Wall St. Rank hold PCRX as of Q3 2014.

  • WealthTrust Fairport reported no remaining Pacira BioSciences position as of Q3 2014 after selling out during the quarter.
  • WealthTrust Fairport sold 100 Pacira BioSciences shares in Q3 2014, an estimated $9K.
  • WealthTrust Fairport first reported a position in Pacira BioSciences in Q2 2014 and held it in 1 quarter.
  • WealthTrust Fairport's Pacira BioSciences position peaked at $9K in Q2 2014.
  • 208 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2014.

Based on WealthTrust Fairport's 13F filing for Q3 2014, filed 13 Nov 2014.